Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

The company recently wowed investors with clinical trial results.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

They have at least one thing in common: An exciting pipeline.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Pierre-Alain Ruffieux of Cytiva discusses key biotech trends including new modalities, AI adoption, supply chain stability, ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

It might pull it off, provided several things fall right in place.

During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso® (API-1), to international pharmaceutical companies as the Company continues advancing global licensing ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...